GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption

被引：0
|
作者：
Bakkour, Waseem [1 ]
Coulson, Ian H. [1 ]
机构：
[1] Burnley Gen Hosp, Dept Dermatol, Burnley, Lancs, England
来源：
DERMATOLOGY AND THERAPY | 2012年 / 2卷 / 01期
关键词：
Anti-CD20 monoclonal antibody; GA101; Lichenoid drug eruption; Rituximab;
D O I：
10.1007/s13555-012-0003-9
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Introduction: Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin's lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established. Case report: The authors report a case of a 62-year-old patient who developed widespread lichenoid eruption as a result of GA101 treatment for his follicular non-Hodgkin's lymphoma. Conclusion: This is the first case report of cutaneous side effects of GA101.
引用
收藏
页数：3
相关论文
共 50 条
  • [41] The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A
    D'Arena, Giovanni
    Grandone, Elvira
    Di Minno, Matteo N. D.
    Musto, Pellegrino
    Di Minno, Giovanni
    [J]. BLOOD TRANSFUSION, 2016, 14 (03) : 255 - 261
  • [42] The Labelling of Monoclonal Antibody Anti-CD20 with Yttrium and Lutetium Radionuclides
    Budsky, Frantisek
    Miler, Vlastimil
    Malek, Zdenek
    [J]. CHEMICKE LISTY, 2009, 103 (01): : 76 - 80
  • [43] The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation
    Pescovitz, MD
    [J]. PEDIATRIC TRANSPLANTATION, 2004, 8 (01) : 9 - 21
  • [44] Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action
    Pescovitz, MD
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (05) : 859 - 866
  • [45] Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)
    Marzano, Angelo V.
    Fanoni, Daniele
    Venegoni, Luigia
    Berti, Emilio
    Caputo, Ruggero
    [J]. DERMATOLOGY, 2007, 214 (04) : 310 - 318
  • [46] Role of anti-CD20 monoclonal antibody in association with immunomodulatory agents
    Bosly, A
    [J]. PATHOLOGIE BIOLOGIE, 2004, 52 (01): : 39 - 42
  • [47] Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
    Mitchell R Smith
    [J]. Oncogene, 2003, 22 : 7359 - 7368
  • [48] Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
    Smith, MR
    [J]. ONCOGENE, 2003, 22 (47) : 7359 - 7368
  • [49] CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
    Jak, Margot
    van Bochove, Gregor G. W.
    Reits, Eric A.
    Kallemeijn, Wouter W.
    Tromp, Jacqueline M.
    Umana, Pablo
    Klein, Christian
    van Lier, Rene A. W.
    van Oers, Marinus H. J.
    Eldering, Eric
    [J]. BLOOD, 2011, 118 (19) : 5178 - 5188
  • [50] Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
    Cheson, Bruce D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : 3525 - 3530
12345